JPH04352962A - Liquid infusing device - Google Patents
Liquid infusing deviceInfo
- Publication number
- JPH04352962A JPH04352962A JP3127886A JP12788691A JPH04352962A JP H04352962 A JPH04352962 A JP H04352962A JP 3127886 A JP3127886 A JP 3127886A JP 12788691 A JP12788691 A JP 12788691A JP H04352962 A JPH04352962 A JP H04352962A
- Authority
- JP
- Japan
- Prior art keywords
- drug
- liquid
- communication port
- solution
- container
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 33
- 229940079593 drug Drugs 0.000 claims abstract description 52
- 239000003814 drug Substances 0.000 claims abstract description 52
- 238000001802 infusion Methods 0.000 claims description 21
- 238000007865 diluting Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 abstract description 20
- 239000012895 dilution Substances 0.000 abstract description 3
- 238000010790 dilution Methods 0.000 abstract description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000003978 infusion fluid Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- NCFTXMQPRQZFMZ-WERGMSTESA-M Cefoperazone sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C([O-])=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 NCFTXMQPRQZFMZ-WERGMSTESA-M 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960002417 cefoperazone sodium Drugs 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920005672 polyolefin resin Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- SVSFIELZISOJDT-XRZFDKQNSA-N (6r,7r)-7-[[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-3-[[1-[2-(dimethylamino)ethyl]tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrochloride Chemical compound Cl.CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 SVSFIELZISOJDT-XRZFDKQNSA-N 0.000 description 1
- REACMANCWHKJSM-DWBVFMGKSA-M Cefsulodin sodium Chemical compound [Na+].C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@@H](C=3C=CC=CC=3)S([O-])(=O)=O)[C@H]2SC1 REACMANCWHKJSM-DWBVFMGKSA-M 0.000 description 1
- URDOHUPGIOGTKV-JTBFTWTJSA-M Cefuroxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 URDOHUPGIOGTKV-JTBFTWTJSA-M 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 229960001931 ampicillin sodium Drugs 0.000 description 1
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- RRYMAQUWDLIUPV-BXKDBHETSA-N cefacetrile Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC#N)[C@@H]12 RRYMAQUWDLIUPV-BXKDBHETSA-N 0.000 description 1
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 1
- 229960003866 cefaloridine Drugs 0.000 description 1
- OJMNTWPPFNMOCJ-CFOLLTDRSA-M cefamandole sodium Chemical compound [Na+].CN1N=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OJMNTWPPFNMOCJ-CFOLLTDRSA-M 0.000 description 1
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 1
- 229960003408 cefazolin sodium Drugs 0.000 description 1
- 229960003791 cefmenoxime Drugs 0.000 description 1
- MPTNDTIREFCQLK-UNVJPQNDSA-N cefmenoxime hydrochloride Chemical compound [H+].[Cl-].S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C.S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C MPTNDTIREFCQLK-UNVJPQNDSA-N 0.000 description 1
- SNBUBQHDYVFSQF-HIFRSBDPSA-N cefmetazole Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSCC#N)OC)CC=1CSC1=NN=NN1C SNBUBQHDYVFSQF-HIFRSBDPSA-N 0.000 description 1
- 229960002676 cefmetazole sodium Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- 229960002727 cefotaxime sodium Drugs 0.000 description 1
- ZQQALMSFFARWPK-ZTQQJVKJSA-L cefotetan disodium Chemical compound [Na+].[Na+].N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C([O-])=O)=O)C(=O)C1SC(=C(C(N)=O)C([O-])=O)S1 ZQQALMSFFARWPK-ZTQQJVKJSA-L 0.000 description 1
- 229960004700 cefotiam hydrochloride Drugs 0.000 description 1
- 229960005446 cefpiramide Drugs 0.000 description 1
- PWAUCHMQEXVFJR-PMAPCBKXSA-N cefpiramide Chemical compound C1=NC(C)=CC(O)=C1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 PWAUCHMQEXVFJR-PMAPCBKXSA-N 0.000 description 1
- ADLFUPFRVXCDMO-LIGXYSTNSA-M ceftizoxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=CCS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 ADLFUPFRVXCDMO-LIGXYSTNSA-M 0.000 description 1
- 229960000636 ceftizoxime sodium Drugs 0.000 description 1
- 229960000534 cefuroxime sodium Drugs 0.000 description 1
- 150000001782 cephems Chemical class 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FWRNIJIOFYDBES-ZQDFAFASSA-L disodium;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[[(2r)-2-phenyl-2-sulfonatoacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [Na+].[Na+].C1([C@H](C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)S([O-])(=O)=O)=CC=CC=C1 FWRNIJIOFYDBES-ZQDFAFASSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229960001520 ranitidine hydrochloride Drugs 0.000 description 1
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Abstract
Description
【0001】0001
【産業上の利用分野】この発明は、輸液装置に関し、更
に詳しくは点滴注射に用いられる輸液装置(容器)に関
する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an infusion device, and more particularly to an infusion device (container) used for intravenous injection.
【0002】0002
【従来の技術】従来より病院等の医療機関においては、
バイアル等の容器に入った粉末薬剤あるいは凍結乾燥剤
を溶解して輸液として点滴注射に用いるが、この際に、
上記薬剤の入った容器とその薬剤の溶解液の入った容器
とを両頭針あるいは連結管等の接続用具を用いて接続し
、溶解液を薬剤の入った容器に移し、薬剤を溶解してい
る。[Prior Art] Conventionally, in medical institutions such as hospitals,
Powdered drugs or freeze-dried drugs in containers such as vials are dissolved and used as an infusion solution for intravenous injection.
The container containing the drug and the container containing the solution of the drug are connected using a connecting tool such as a double-ended needle or a connecting tube, and the solution is transferred to the container containing the drug to dissolve the drug. .
【0003】ところがこの操作は繁雑で手間がかかる上
に、外気中で薬剤の入った容器に接続用の穴をあける操
作を行なうので、中の薬剤が汚染される可能性がある。[0003] However, this operation is complicated and time-consuming, and since the connection hole is made in the container containing the drug in the open air, there is a possibility that the drug inside may become contaminated.
【0004】そこで上記のような問題を解消したものと
して、特表昭61−501129号公報に示されるよう
な輸液装置(容器)が提案されている。[0004] In order to solve the above-mentioned problems, an infusion device (container) as disclosed in Japanese Patent Publication No. 1988-501129 has been proposed.
【0005】この輸液装置は図4に示されているように
、薬剤容器であるバイアル(101)を収容するカプセ
ル(102)と、薬液取出口を有する溶解液の入った可
撓性容器(103)とが、チューブ(104)で接続さ
れたものである。そしてチューブ(104)内には、バ
イアル(101)側に中空の穿刺針(105)が取りつ
けられ、可撓性容器(103)側に破断部材(106)
が取りつけられている。前記破断部材(106)はチュ
ーブ(104)内の通路を閉じており、液体の流通を阻
止している。As shown in FIG. 4, this infusion device includes a capsule (102) containing a vial (101) which is a drug container, and a flexible container (103) containing a solution having a drug solution outlet. ) are connected by a tube (104). Inside the tube (104), a hollow puncture needle (105) is attached to the vial (101) side, and a breaking member (106) is attached to the flexible container (103) side.
is attached. The breaking member (106) closes the passage within the tube (104) and prevents the flow of liquid.
【0006】使用に際しては、カプセル(102)上部
のキャップ(107)を指で押してバイアル(101)
を押し下げ、穿刺針(105)でバイアル(101)の
ゴム栓(108)を貫き可撓性容器(103)とバイア
ル(101)とをまず連結する。ついで、チューブ(1
04)内の前記破断部材(106)を手で折り曲げ、そ
れによりチューブ(104)内の通路を開通させ、薬剤
と溶解液とを混合するようになっている。In use, press the cap (107) on the top of the capsule (102) with your finger to remove the vial (101).
is pushed down and the puncture needle (105) pierces the rubber stopper (108) of the vial (101) to first connect the flexible container (103) and the vial (101). Next, the tube (1
The breaking member (106) in the tube (104) is manually bent to open a passage in the tube (104) and mix the drug and the solution.
【0007】[0007]
【発明が解決しようとする課題】しかしながら、前記輸
液装置において、薬剤容器と溶解液の入った可撓性装置
とを連通して混合する点に関しては、改良されたとは言
うものの、穿刺針(105)によってバイアル(101
)のゴム栓(108)を刺通したのち、破断部材(10
6)を手で折って通路を開けなければならず、まだかな
り手間を要するものである。また破断部材(106)の
折れ方が不完全な場合には、液が通りにくく、溶解に時
間がかかるという問題がある。更に部品点数が多いので
コストが高くなるという問題もあった。[Problems to be Solved by the Invention] However, in the above-mentioned infusion device, although it has been improved in communicating and mixing the drug container and the flexible device containing the solution, the puncture needle (105 ) by vial (101
) is pierced through the rubber stopper (108), and then the breakable member (10
6) by hand to open the passage, which still requires considerable effort. Furthermore, if the breakable member (106) is imperfectly bent, there is a problem in that it is difficult for the liquid to pass through and it takes a long time to dissolve. Furthermore, since there are many parts, there is also the problem that the cost is high.
【0008】この発明はこのような問題に鑑みてなされ
たもので、薬剤容器と溶解液や希釈液(以下、溶解液と
いう)の容器との連通を簡単な構成で確実かつ容易にし
、連通後の薬剤と溶解液の混合を短時間で行うことがで
き、しかもコストが安い輸液装置を提供することを目的
とする。[0008] The present invention was made in view of the above-mentioned problems, and it ensures and facilitates communication between a drug container and a container for dissolving liquid or diluting liquid (hereinafter referred to as dissolving liquid) with a simple structure, and after communication. To provide an infusion device that can mix a drug and a solution in a short time and is inexpensive.
【0009】[0009]
【課題を解決するための手段及び作用】この発明は、内
部に溶解液又は希釈液が収納され、上部に液体連通口を
有する液体容器と、内部に薬剤が収納され、下部に薬剤
連通口を有する薬剤容器と、前記液体連通口及び薬剤連
通口の間に介設され、操作により両連通口を連通状態に
切換可能な栓体とからなる輸液装置である。[Means and Effects for Solving the Problems] The present invention provides a liquid container in which a dissolving solution or a diluent is stored and a liquid communication port in the upper part, and a liquid container in which a drug is stored in the interior and a drug communication port in the lower part. This infusion device includes a drug container having a drug container, and a stopper that is interposed between the liquid communication port and the drug communication port and can be operated to switch both communication ports into a communicating state.
【0010】すなわち、この発明は、栓体の切換操作に
より薬剤容器の下部(薬剤容器の首部、実施例の図1に
おいて下部)の薬剤連通口と、液体容器の上部(実施例
の図1において上部)の液体連通口とを連通状態にし、
それによって薬剤容器及び液体容器の各連通口の開放を
行い、それによって薬剤と溶解液又は希釈液とを混合し
、輸液を調製できる。That is, in the present invention, by switching the stopper, the drug communication port at the lower part of the drug container (the neck of the drug container, the lower part in FIG. 1 of the embodiment) and the upper part of the liquid container (the neck of the drug container, the lower part in FIG. 1 of the embodiment) is connected. Connect the liquid communication port (upper part) to the liquid communication port,
This opens the communication ports of the drug container and the liquid container, thereby allowing the drug and the solution or dilution solution to be mixed to prepare an infusion.
【0011】要するに、栓体を回転方向移動又は軸方向
移動させるという単純な操作だけで、確実に輸液を調製
できるわけである。In short, an infusion can be reliably prepared by simply moving the stopper in the rotational or axial direction.
【0012】0012
【実施例】以下、図に示す実施例に基づきこの発明を詳
述する。なお、これによってこの発明が限定されるもの
ではない。DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will now be described in detail based on embodiments shown in the drawings. Note that this invention is not limited to this.
【0013】まず、図1において、輸液装置(容器)(
1)は、内部に溶解液が滅菌状態で収納され、上部に液
体連通口(2)を有する可撓性容器(以下、バッグとい
う)(3)と、内部に固体状の薬剤が無菌状態で収納さ
れ、下部に薬剤連通口(4)を有する薬剤容器としての
薬剤バイアル(以下、バイアルという)(5)と、バッ
グ(3)の液体連通口(2)とバイアル(5)の薬剤連
通口(4)との間に介設された栓体(6)とを備えてい
る。なお、(7)はバッグ(3)の下部に設けられた輸
液取出口である。First, in FIG. 1, an infusion device (container) (
1) consists of a flexible container (hereinafter referred to as a bag) (3) in which a solution is stored in a sterile state and a liquid communication port (2) at the top, and a solid drug is stored in a sterile state. A drug vial (hereinafter referred to as a vial) (5) as a drug container that is stored and has a drug communication port (4) at the bottom, a liquid communication port (2) of the bag (3), and a drug communication port of the vial (5). (4) and a stopper (6) interposed between the stopper and the stopper (6). Note that (7) is an infusion solution outlet provided at the bottom of the bag (3).
【0014】バッグ(3)は、軟質の塩化ビニル樹脂や
ポリオレフィン系樹脂、エチレン酢酸ビニル共重合体な
どの可撓性に富む材料で形成された容器である。なおポ
リオレフィン系樹脂は耐薬品に優れ、溶解液中への溶出
物も少ないので好ましい。The bag (3) is a container made of a highly flexible material such as soft vinyl chloride resin, polyolefin resin, or ethylene-vinyl acetate copolymer. Note that polyolefin resins are preferable because they have excellent chemical resistance and less eluate into the solution.
【0015】バッグ(3)に入られる溶解液としては、
たとえば生理食塩水、5%ブドウ糖液、注射用蒸溜水の
ほか、各種の電解質を含む溶液が用いられる。[0015] The solution to be put into the bag (3) is as follows:
For example, in addition to physiological saline, 5% glucose solution, and distilled water for injection, solutions containing various electrolytes are used.
【0016】バイアル(5)(容器本体部分)は公知の
ガラス製またはプラスチック製のバイアルであり、内部
には固体状の薬剤が入れられている。The vial (5) (container body portion) is a known glass or plastic vial, and a solid drug is placed inside.
【0017】バイアル(5)に入れられる薬剤の一例と
しては次のものがある。抗生物質としては、セファゾリ
ンナトリウム、セフチゾキシムナトリウム、塩酸セフォ
チアム、塩酸セフメノキシム、セファセトリルナトリウ
ム、セファマンドールナトリウム、セファロリジン、セ
フォタキシムナトリウム、セフォテタンナトリウム、セ
フォペラゾンナトリウム、セフスロジンナトリウム、セ
フテゾールナトリウム、セフピラミドナトリウム、セフ
メタゾールナトリウム、セフロキシムナトリウムなどの
セフェム系抗生物質、またアンピシリンナトリウム、カ
ルペニシリンナトリウム、スルベニシリンナトリウム、
チカルシリンナトリウムなどのペニシリン系抗生物質が
ある。抗腫瘍剤としては、マイトマイシンC、フルオロ
ウラシル、テガフール、シタラビン、などがある。抗漬
瘍剤としては、ファモチジン、塩酸ラニチジン、シメチ
ジンなどがある。[0017] Examples of drugs that can be placed in the vial (5) include the following: Antibiotics include cefazolin sodium, ceftizoxime sodium, cefotiam hydrochloride, cefmenoxime hydrochloride, cefacetril sodium, cefamandole sodium, cephaloridine, cefotaxime sodium, cefotetan sodium, cefoperazone sodium, cefsulodine sodium, and cefoperazone sodium. Cephem antibiotics such as tezol sodium, cefpiramide sodium, cefmetazole sodium, and cefuroxime sodium, as well as ampicillin sodium, carpenicillin sodium, sulbenicillin sodium,
There are penicillin antibiotics such as ticarcillin sodium. Antitumor agents include mitomycin C, fluorouracil, tegafur, cytarabine, and the like. Anti-ulcer agents include famotidine, ranitidine hydrochloride, and cimetidine.
【0018】栓体(6)は、連通路(8)を形成した本
体部(9)と、この連通路を右方向(図1において)に
引っ張り出すことにより開放可能に閉塞する操作体(1
0)と、連通路(8)の下部をバッグ(3)の液体連通
口(2)に連通させるべく液体連通口を係止させる下フ
ランジ(11)と、連通路(8)の上部をバイアル(5
)の薬剤連通口(4)に連通させるべく薬剤連通口(4
)を係止させる上フランジ(12)とから主としてなる
。なお、(13)は操作体(10)の通口、(14)は
当て板である。操作体(10)は気密性の良好な材料で
形成される必要があり、好ましくはシリコンゴムで形成
される。The stopper (6) includes a main body (9) forming a communication path (8), and an operating body (1) that can be opened and closed by pulling the communication path to the right (in FIG. 1).
0), a lower flange (11) that locks the liquid communication port so that the lower part of the communication path (8) communicates with the liquid communication port (2) of the bag (3), and a lower flange (11) that locks the liquid communication port so that the lower part of the communication path (8) communicates with the liquid communication port (2) of the bag (3); (5
) to communicate with the drug communication port (4) of the drug communication port (4).
) and an upper flange (12) for locking. Note that (13) is a port for the operating body (10), and (14) is a backing plate. The operating body (10) needs to be made of a material with good airtightness, and is preferably made of silicone rubber.
【0019】次に以上の構成からなる輸液装置(1)の
使用方法を説明する。まず輸液装置(1)の使用に際し
ては、図1に示す栓体(6)の操作体(10)を、図2
に示すごとく右方向に当て板(14)が本体部(9)の
内部壁に当接するまで引っ張り出すことによってちょう
ど連通路(8)を最大開放し、バッグ(3)の液体連通
口(2)とバイアル(5)の薬剤連通口(4)とを連通
させる。かくしてバッグ(3)内の溶解液とバイアル(
5)内の薬剤とを混合させ、所定の輸液を調製すること
ができる。Next, a method of using the infusion device (1) having the above structure will be explained. First, when using the infusion device (1), the operation body (10) of the stopper (6) shown in FIG.
As shown in the figure, by pulling the backing plate (14) to the right until it contacts the inner wall of the main body (9), the communication passage (8) is opened to the maximum, and the liquid communication port (2) of the bag (3) is opened. and the drug communication port (4) of the vial (5). Thus, the solution in the bag (3) and the vial (
5) can be mixed with the drugs mentioned above to prepare a predetermined infusion solution.
【0020】かくして、バック(3)に断続的な圧縮を
加えるか又は輸液装置(1)を図1とは上・下を逆にす
ることによって、バッグ(3)内の溶解液をバイアル(
5)へ往復移動させ、バイアル(5)中の薬剤を溶解し
、均一な輸液が輸液装置(1)内、つまりバイアル(5
)とバッグ(3)との連結容器内に得られる。[0020] Thus, by applying intermittent compression to the bag (3) or by turning the infusion device (1) upside down compared to FIG.
5), the drug in the vial (5) is dissolved, and a homogeneous infusion is distributed within the infusion device (1), that is, vial (5).
) and the bag (3) in a connecting container.
【0021】以上のごとく、輸液装置(1)は、部品点
数が少なく、しかも輸液の調製が単に栓体(6)の操作
体(10)を引っ張るだけで行えるので簡単でかつ確実
である。As described above, the infusion device (1) has a small number of parts and is simple and reliable since the infusion can be prepared by simply pulling the operating body (10) of the stopper (6).
【0022】以上の実施例とは異なり、栓体の操作体は
、直線方向の移動ではなく回転方向の移動によって、連
通路の開閉を行なえるように構成できる。例えば図3に
おいて、栓体(26)の操作体(30)は、90°の回
転操作によって、通口(33)を介してバイアル(25
)の薬剤連通口(24)とバッグ(23)の液体連通口
(22)とを連通させるよう構成してもよい。なお、図
3の例ではバイアル(25)とバッグ(23)とはプラ
スチックで一体の円柱状に成形され、栓体(26)はそ
の円柱体の横胴を貫通し、係止するよう装着されている
。(27)は輸液取出口、(28)は連絡路、(35)
はバイアル(25)の上部に設けられ輸液装置(21)
全体を吊る吊り孔である。Different from the above embodiments, the operating body of the stopper can be constructed so that it can open and close the communicating passage by moving not in a linear direction but in a rotational direction. For example, in FIG. 3, the operating body (30) of the stopper (26) is rotated by 90° to insert the vial (25) through the opening (33).
) may be configured to communicate with the drug communication port (24) of the bag (23) and the liquid communication port (22) of the bag (23). In the example shown in FIG. 3, the vial (25) and the bag (23) are made of plastic and are integrally molded into a cylindrical shape, and the stopper (26) is attached so as to penetrate through the lateral body of the cylindrical body and lock. ing. (27) is the infusion outlet, (28) is the communication path, (35)
is provided on the top of the vial (25) and the infusion device (21)
This is a hanging hole for hanging the whole thing.
【0023】[0023]
【発明の効果】この発明によれば、容易にかつきわめて
確実な連通が得られ、しかも部品点数が少なくコストも
安い。According to the present invention, communication can be easily and extremely reliable, and the number of parts is small and the cost is low.
【図1】この発明の一実施例を示す縦断面図である。FIG. 1 is a longitudinal sectional view showing an embodiment of the present invention.
【図2】この実施例の使用状態を示す要部拡大図である
。FIG. 2 is an enlarged view of main parts showing the usage state of this embodiment.
【図3】他の実施例を示す図1相当図である。FIG. 3 is a diagram corresponding to FIG. 1 showing another embodiment.
【図4】従来例を示す一部断面を含む正面図である。FIG. 4 is a front view including a partial cross section showing a conventional example.
1 輸液装置 2 液体連通口 3 バッグ(可撓製容器) 4 薬剤連通口 5 薬剤バイアル(薬剤容器) 6 栓体 10 操作体 1 Infusion device 2 Liquid communication port 3 Bag (flexible container) 4 Drug communication port 5 Drug vial (drug container) 6 Plug body 10 Operation body
Claims (1)
上部に液体連通口を有する液体容器と、内部に薬剤が収
納され、下部に薬剤連通口を有する薬剤容器と、前記液
体連通口及び薬剤連通口の間に介設され、操作により両
連通口を連通状態に切換可能な栓体とからなる輸液装置
。[Claim 1] A dissolving solution or a diluting solution is stored inside,
A liquid container having a liquid communication port in the upper part, a drug container storing a drug inside and having a drug communication port in the lower part, and a drug container interposed between the liquid communication port and the drug communication port, and both communication ports can be opened by operation. An infusion device consisting of a stopper that can be switched to a communicating state.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3127886A JPH04352962A (en) | 1991-05-30 | 1991-05-30 | Liquid infusing device |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3127886A JPH04352962A (en) | 1991-05-30 | 1991-05-30 | Liquid infusing device |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH04352962A true JPH04352962A (en) | 1992-12-08 |
Family
ID=14971090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3127886A Pending JPH04352962A (en) | 1991-05-30 | 1991-05-30 | Liquid infusing device |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH04352962A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100855538B1 (en) * | 2005-05-27 | 2008-09-01 | 혼다 기켄 고교 가부시키가이샤 | Walking assisting device |
JP2011016581A (en) * | 2009-06-11 | 2011-01-27 | Masaharu Shinobe | Beverage container |
-
1991
- 1991-05-30 JP JP3127886A patent/JPH04352962A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100855538B1 (en) * | 2005-05-27 | 2008-09-01 | 혼다 기켄 고교 가부시키가이샤 | Walking assisting device |
JP2011016581A (en) * | 2009-06-11 | 2011-01-27 | Masaharu Shinobe | Beverage container |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0533171A1 (en) | Transfusion device | |
US5352191A (en) | Transfusion device | |
JPH05212090A (en) | Transfusion container | |
EP0503867B1 (en) | storing and mixing apparatus | |
JP2003135563A (en) | Small bag-shaped medicine container | |
JPH0572830B2 (en) | ||
JPH06239352A (en) | Solution injection set | |
JPH0236261B2 (en) | ||
US5261902A (en) | Fluid container assembly | |
JPH04352962A (en) | Liquid infusing device | |
JP4552271B2 (en) | Liquid transfer tool | |
JP2630185B2 (en) | Infusion device | |
JPH07171192A (en) | Infusion vessel | |
JP3345860B2 (en) | Infusion container | |
JP2555143Y2 (en) | Infusion device | |
JPH04327850A (en) | Liquid transfusing device | |
JPH07184979A (en) | Vessel for infusion | |
JPH04329957A (en) | Germ-free holding/mixing apparatus for two kinds of medicines held in individually sealed container | |
JPH04282160A (en) | Transfusion liquid container | |
JP3213928B2 (en) | Dissolution liquid container provided with means for communicating with the drug container | |
JPH053905A (en) | Liquid transfer device | |
EP1084692A1 (en) | Liquid container | |
JPH04367663A (en) | Transfusion device | |
JPH04367664A (en) | Transfusion device | |
JPH05192376A (en) | Transfusing device |